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Case presentation
A 22-year-old woman came to the Yale-New Haven Hospital 25 years
ago with arthralgias and a malar rash. A lupus preparation was positive,
and treatment with prednisone moderately improved her arthralgias.
Three years later, her urine contained protein, red cells, and red cell
casts. The serum creatinine was normal. A renal biopsy performed 21
years ago revealed a diffuse proliferative lupus glomerulonephritis with
necrosis and subendothelial deposits. This lesion currently would be
classified as WHO class IV-B with an activity index of 9 and a
chronicity index of 0. She was treated with azathioprine and pred-
nisone; her proteinuria resolved and treatment was discontinued after a
total of 24 months of therapy.
Nineteen years ago the proteinuria returned, the urine sediment again
became active, and the DNA binding was elevated, as evidenced by the
Fahr test. The blood pressure was normal and serum creatinine was 1.4
mg/dl. Because of the clinical reactivation of her disease, a second renal
biopsy was performed, which disclosed diffuse lupus glomerulonephri-
tis with necrosis and sclerosis. Classification under the current system
would be WHO class IV-C with an activity index of 12 and a chronicity
index of 2. Prednisone and azathioprine therapy was reinitiated. A
repeat biopsy, performed 17 years ago to determine whether cytotoxic
therapy could be discontinued, showed persistence of a diffuse lupus
glomerulonephritis and increased sclerosis. The current classification
would assign this lesion an activity index of 4 and a chronicity index of
4. The cytotoxic therapy was continued, and her proteinuria remitted,
She had no proteinuria between 13 and 17 years ago. Her creatinine
clearance was stable, and renal biopsy was performed to determine the
usefulness of continuing azathioprine. This fourth biopsy revealed
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persistence of the diffuse lupus glomerulonephritis pattern and advanc-
ing sclerosis; the activity index by current criteria would have been 4,
and the chronicity index, 6. Azathioprine therapy was stopped, but
low-dose steroids were continued for management of extrarenal mani-
festations of lupus. Two years later, she developed herpes zoster,
which was associated with anemia and leukopenia. A chest radiograph
at that time revealed multiple bilateral nodules. Sputum cultures were
negative. She developed headaches and seizures. A bone marrow study
revealed panhypocellularity. Urinalysis disclosed 4+ proteinuria with
an active urinary sediment.
Because of thrombocytopenia, no renal biopsy was performed, and a
clinical diagnosis of lupus exacerbation with recurrent nephritis, lupus
cerebritis, lupus pneumonitis, and pancytopenia was made. Aggressive
treatment with prednisone and cyclophosphamide was followed by
marked clinical improvement. Nine years ago, all therapy was discon-
tinued, and she felt remarkably well for the next 6 years. She had little
arthritis and no significant proteinuria. The serum creatinine was stable
at 1.1 mgldl, and the creatinine clearance was 70-80 cc/mm. The
antinuclear antibody (ANA) remained positive at 1:256. Two years ago,
she developed a viral syndrome with recurrence of arthritis. The ANA
rose to a titer of 1:2560, with a positive anti-native DNA. She was
treated with prednisone and nonsteroidal antiinflammatory agents. Her
arthritis became more severe over the following year, and last year a
followup ANA revealed an increase in titer to 1:5120; she also had
positive anti-Smith, anti-Ro, anti-La, anti-U l-RNP, and anti-double
stranded DNA. Steroid therapy was continued, but cytotoxic agents
were not added.
Early this year, she again had a viral syndrome, and was found for the
first time to have hypertension. The arthritis was more severe, the
serum creatinine had risen to 1.4 mgldl, and the creatinine clearance
had fallen to 38 cc/mm; the urine contained protein (4.2 glday) and red
cells. A fifth renal biopsy showed a focal and segmental necrotizing
lupus glomerulonephritis with an active interstitial nephritis, WHO
class Ill with an activity index of 8 and a chronicity index of 6. The
biopsy specimen contained evidence of fibrin deposition within the
capillary loops, a finding consistent with the presence of anti-cardiolipin
antibodies. Prednisone (60 mg/day) and cyclophosphamide (50 mg/day)
therapy were reinstituted.
Discussion
Da. MICHAEL KASHGARIAN (Professor of Pathology and
Biology, Yale University, and Director, Renal Pathology and
Electron Microscopy, Yale-New Haven Hospital, New Haven,
Connecticut): This patient demonstrates the complex nature of
lupus nephritis with its protean manifestations and unusual
clinical features. She also demonstrates the role and clinical
significance of the renal biopsy in the management of this
disease.
Numerous reports have documented the unpredictable
course of lupus nephritis and the role of renal biopsy in the
evaluation of individual patients with isolated and unusual
clinical features [1—4]. For example, some patients who have no
clinical evidence of renal involvement have severe forms of
lupus nephntis on biopsy, whereas others initially present with
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Table 1. WHO classification of lupus nephritis
Immunofluorescence
Disease Light microscopy Electron microscopy microscopy Clinical features
WHO class I No lesion No lesion No deposits Negative, normal urine
(normal)
WHO class II Minimal changes Mesangial deposits Mesangial IgG, C3; Mild to moderate proteinuria,
(mesangial) hypercellullarity occasionally active
sediment
A
B Mild mesangial proliferation
WHO class III Focal and segmental necrosis Mesangial and Granular capillary and Proteinuria, active sediment
(focal and proliferation subendothelial deposits mesangial Ig, C3
segmental)
WHO class IV Mesangial and endocapillary Endothelial and marked Same as class III; "full Acute nephritis with active
(diffuse) proliferation;
membranoproliferative and/
or crescentic pattern.
Leukocytic infiltration
mesangial proliferation;
mesangial,
subendothelial and
sometimes subepithelial
deposits
house pattern" sediment and/or nephrotic
syndrome
WHO class V Diffuse membranous Epi- and intramembranous Peripheral granular Nephrotic syndrome or
(membranous) thickening, mesangial
prominence
deposits; frequently
mesangial deposits
IgG, C3 severe proteinuria
renal disease but exhibit systemic manifestations only later in
their course [5—8]. Thenature of the lesion on renal biopsy gives
direct information relating to the severity of the autoimmune
response within the kidney, thereby aiding in predicting both
short-term and long-term outcome and in selecting appropriate
therapy.
Before addressing the substance of this Forum, I'd like to
begin by reviewing some fundamentals of the antigens and
antibodies involved in the pathogenesis of lupus nephritis. The
types of antibodies found in patients with lupus are extremely
varied, and the nature of the antigens and the antibodies
directed against them is important for an adequate understand-
ing of some aspects of the pathogenesis of the renal lesions [9].
Let me provide some background. The DNA of our genome is
wrapped around a central core of histones to form the nucleo-
somes. Surrounding each nucleosome are two strands of native
DNA exposing only a portion of the histone core, which is
composed of a tetramer of different histone proteins, two of
which—.-H2B and H2A—have access to the surface of the
nucleosome. The histone called Hi is external. Many patients
with lupus develop antibodies to the histones Hi, H2B, and
H2A as well as to the DNA. Following transcription of RNA
from the DNA, the RNA must be processed to remove the
"nonsense" information contained in introns. This molecular
debndement is accomplished in the spliceosome utilizing a
group of small nuclear ribonucleoproteins (snRP); the UlsnRPs
are a complex of nine proteins associated with Ul RNA. The
anti-Sm antibody recognizes some of the polypeptides associ-
ated with Ui RNA and is usually accompanied by anti-Ui RNP
antibodies.
Of major importance is the absence of evidence that lupus
patients harboring these antibodies have any alteration of
nuclear function. Several critical characteristics of the antigens
are important in the pathogenesis of lupus nephritis, however.
Histones are lysine rich and therefore cationic. During RNA
splicing, the spliceosomes are intimately associated with ubiq-
uitin, and the nonsense RNA is rapidly ubiquitinized (defined as
the binding of denatured proteins to ubiquitin) in preparation for
degradation; ubiquitinization also increases the cationic charge
of the antigens.
After the RNA is spliced, it must be transported out of the
nucleus to the ribosomes; the transport process is accomplished
with the aid of the hYi small cytoplasmic ribonucleoproteins
(hyl RNA). Initially associated with the spliceosomes, the hyl
RNA then are moved ("translocated") to the cytoplasm. The
hYl RNA is associated with two different proteins, Ro and La,
one probably intranuclear, the other cytoplasmic. Evidence
indicates that these two proteins do not bind to the hYl RNA at
the same time. Because these two proteins are binding proteins,
however, they can confer certain characteristics on the mole-
cules to which they attach, and make these molecules more
susceptible to ubiquitinization, or they can make these mole-
cules cationic by virtue of the protein's lysine-rich regions.
The different microscopic patterns associated with anti-nu-
clear antibodies are also related to the various specificities. For
instance, the speckled pattern is associated with the presence of
antibodies to the Ui RNPs as well as to Smith, Ro, and La.
Clinical-pathologic correlations of varying degrees have been
associated with these antibodies. While the presence of anti-
native or double-stranded DNA is the most specific finding for
the diagnosis of lupus, antibodies to the small ribonuclear
proteins also are more common in lupus than in other rheumatic
diseases. The significance of antibodies to Smith, Ro, and La is
not entirely clear, but a recent study by Tokano et al has
demonstrated that, as a group, patients with these antibodies
have several distinguishing characteristics. (1) They are more
likely to have antibodies of class IgGl or IgG3; (2) they are
more likely to have higher titers of anti-double-stranded DNA;
and (3) they tend to have severe lupus glomerulonephntis and
lupus cerebritis [10]. These findings suggest that the presence of
anti-Smith antibodies is associated with a greater severity of
disease. This observation is not surprising, as IgG classes 1 and
3 bind complement and therefore might be expected to be
associated with a more severe inflammatory response.
Let me turn now to the pathologic features of lupus nephritis.
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The World Health Organization (WHO) developed a classifica-
tion scheme for lupus nephritis in an effort to sort out the
extremely varied renal manifestations of the disease (Table 1)
[11]. It was hoped that more accurate classification would result
in improved clinical management of patients. This classification
system, now in general use, has been widely accepted by
clinical nephrologists and renal pathologists alike. The system
combines all the morphologic modalities of biopsy interpreta-
tion, and its value has been augmented by the use of semiquan-
titative assessment of activity and chronicity based solely on
morphologic findings. Because many clinicians advocate per-
forming a renal biopsy as a routine part of the evaluation of all
patients with SLE, it is especially important that one under-
stand the specific contribution of biopsy-derived information in
clinical management. Among the questions I will attempt to
answer in this Forum are: Using the existing WHO classifica-
tion, how closely can one predict clinical response to therapy
and long-term prognosis from the morphologic findings? Do
most patients fit into one of the WHO classes? Can quantifica-
tion of acute inflammatory changes ("activity index") predict
response to therapy? Does quantification of the so-called
"chronicity index" assist in predicting long-term outcome?
What is the importance of interstitial lesions? And, finally, a
question raised by the patient presented here: when is another
biopsy indicated? I will address these questions by reviewing
the pathology and pathogenesis of the renal manifestations of
lupus.
Clinical-pathologic correlations have proved useful in and of
themselves, but their value is enhanced when one considers the
pathogenesis of various lesions observed. Over the past three
decades, major advances have furthered our understanding of
the pathogenesis of immune-complex-mediated glomerular in-
jury. Biopsy findings must be interpreted in the context of what
we have learned from experimental models [12—17]. This prin-
ciple is particularly applicable in the case of lupus nephritis,
because the pathogenesis of the renal lesions in this disease is
thought to closely resemble that of various forms of experimen-
tal immune-complex glomerulonephritis [18—25]. Indeed, we
have known for more than 20 years that assessment of renal
biopsies by light, immunofluorescence, and electron micros-
copy demonstrates patterns of glomerular injury in patients
with lupus that mimic those seen in experimental models [26].
The various patterns of lupus nephritis are best considered,
therefore, in the context of the potential pathogenetic mecha-
nisms that might be involved in their evolution. Analysis in this
way not only might give us a basis to correlate with clinical
outcome, but it also might offer a rationale for therapeutic
manipulation. I will summarize the WHO classification in the
context of what we know about the potential pathogenetic
mechanisms that underlie the various lesions.
A class-I renal biopsy specimen reveals essentially a normal
kidney by light, electron, and immunofluorescence microscopy.
Minor nonspecific changes occasionally are observed on elec-
tron microscopy, but these changes usually are not associated
with a functional abnormality. Since this class is defined, in
reality, by the absence of morphologic evidence of glomerular
damage, it denotes a lack of significant renal involvement in
SLE.
Class II, comprising pure mesangial lesions, has been subdi-
vided into class hA and class IIB. The former contains lesions
with minimal or no significant changes by light microscopy,
although immunofluorescence can yield evidence of immune
deposits confined to the mesangium, and electron microscopy
can reveal corresponding electron-dense deposits in the me-
sangium. In class IIB, light microscropy shows definite glomer-
ular mesangial hypercellularity confined to the centrilobular
areas away from the vascular pole. The peripheral glomerular
capillary walls exhibit no significant changes. Immunofluores-
cence reveals mesangial immunoglobulin deposition, and elec-
tron microscopy discloses dense deposits confined to the me-
sangial regions but occasionally present as well in the
paramesangial subendothelial areas. Tubular, interstitial, and
vascular changes usually are insignificant. Patients with class-I!
lesions generally have minimal clinical evidence of renal in-
volvement with mild to moderate proteinuria and hematuria and
little or no evidence of renal insufficiency. Experimental studies
that have produced lesions resembling class II have involved
the generation of relatively small numbers of stable immune
complexes of intermediate size formed with antibodies having
high affinity and avidity [13]. The filtration mechanisms present
within the mesangial clearing system can remove complexes of
intermediate size from the glomerular capillary [271. The rela-
tively small number of complexes characteristic of this lesion
prevents the mesangial system from becoming overloaded and
allows the complexes to be sequestered in the mesangium
where they are subject to degradation and removal rather than
remaining at sites where they could activate inflammatory
mediators. Thus, the deposition of complexes in the mesangium
alone, in the presence of an intact mesangial clearing capacity,
results in a lesion with widening of the mesangial areas by
immune complexes but without evidence of active inflamma-
tory infiltrate. This explanation of accumulation of immune
complexes in the mesangium currently assigns no specific
characteristics either to the nature of the antigen or to the
nature of the antibody [23—25]. Increasing evidence, however,
suggests that specific characteristics of both antigen and anti-
body are involved in localization of complexes to distinct
glomerular sites. Given that fibronectin is present in the me-
sangium, and given its capacity to interact with aggregates of
immunoglobulins and immune complexes in the circulation,
fibronectin might play a role in mesangial localization. This
mechanism has been implicated in the preferential mesangial
deposition of immune complexes containing IgA [28]. Regard-
less of the mechanisms involved in mesangial localization, the
sequestration of such complexes to this site allows for their
isolation from inflammatory mediators and results in a nonin-
flammatory "benign" lesion.
Class III is characterized by light microscopic findings of a
focal and segmental glomerulonephritis. Generally, less than
50% of the glomeruli are involved, and those that are involved
show only focal damage, occupying less than 50% of the
glomerular surface. The segmental changes can be proliferative,
necrotizing, scierosing, or a combination of these alterations.
Segmental intracapillary and extracapillary cell proliferation
with obliteration of the capillary lumina is sometimes found in
addition to mesangial widening, as seen in class-Il lesions.
Immunofluorescence and electron microscopic findings show
major differences in comparison to class II. Immunofluores-
cence reveals peripheral granular as well as mesangial deposi-
tion of immunoglobulins, and electron microscopy discloses
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subendothelial in addition to mesangial deposits. The similarity
of the immunofluorescence and electron microscopic findings of
class III to those of class IV, which I will describe in a moment,
suggest that these two classes actually might be variations of
the same immunopathologic lesion, with the focal nature of
class II representing a quantitative rather than a qualitative
difference. Class III has been broken down into three sub-
classes: active necrotizing lesions; necrotizing and scierosing
lesions; and purely sclerosing lesions. The clinical significance
of this subclassification is not clear. The natural history of
patients with class-Ill lesions is similar to that of patients
having class-IV lesions [29, 30]; again, classes III and IV might
prove to be a continuum of the same lesion.
Class IV is characterized by diffuse proliferative glomerulo-
nephritis. The majority or all of the glomeruli are involved, and
each glomerulus shows diffuse hypercellularity. As with class
III, segmental areas of necrosis can occur. A variety of other
changes also can be seen and might relate to the degree of
disease activity and/or the chronicity of the process. Focal
areas of crescent formation can be present, and these generally
are associated with segmental necrosis. Nuclear debris repre-
sented by hematoxylin bodies also can be present. Some
segments of peripheral capillary loop can be dramatically
thickened to form the so-called "wire ioop" lesion. Segmental
areas of sclerosis are an indicator either of previous segmental
necrosis or, more likely, of chronicity. The lesions encountered
range from diffuse mesangial hypercellularity without necrosis,
sclerosis, or wire ioops, to a severe necrotizing and crescentic
glomerulonephritis with focal or global areas of sclerosis.
Immunofluorescence microscopy reveals a coarsely granular
pattern of immunoglobulin deposition both in the mesangium
and in the peripheral capillary walls. Multiple immunoglobulins
are frequently encountered and generally are accompanied by
evidence of activation of inflammatory mediators such as dep-
osition of complement components, fibrinogen, and properdin.
Electron microscopic examination is similar to that seen with
class III. Abundant subendothelial deposits are accompanied
by large mesangial deposits. Subepithelial and intramembra-
nous deposits are also identified frequently. Mesangial hyper-
cellularity with circumferential mesangial interposition, fre-
quently present, is associated with the light microscopic pattern
of a mesangiocapillary glomerulonephritis. Occasionally, the
electron-dense deposits show an organized or crystalline pat-
tern, which has been termed a "fingerprint" pattern. This
organized appearance is most frequently seen in the presence of
abundant subendothelial deposits but can be present in all
classes of lupus nephritis. The crystalline structure is thought
by some to suggest the presence of cryoglobulins because
similar structures are seen in patients with idiopathic mixed
cryoglobulinemia [311. They might represent a pattern of crys-
talline DNA [32]. Endothelial cell swelling and proliferation are
prominent. Occasional mitotic figures of glomerular cellular
components suggest active proliferation and regeneration sec-
ondary to activation of inflammatory cytokines and growth
factors. Intraendothelial tubulovesicular structures resembling
myxoviruses have been identified in a majority of all patients
with lupus nephropathy. The significance of these structures is
unclear, but some evidence suggests that they are induced by
alpha interferon [33].
The localization of immune complexes to the subendothelial
region where they have access to plasma inflammatory media-
tors is the critical step in initiating the inflammatory response.
Experimental studies that have examined the logistics of im-
mune-complex localization in the subendothelial region have
demonstrated that localization at this site occurs with larger
numbers of intermediate-sized complexes or with large com-
plexes formed by high-affinity antibodies [12, 13]. It is likely
that the mesangium's ability to clear these macromolecules is
overtaxed, and that these complexes accumulate, initially in the
paramesangial subendothelial location, and then ultimately in
the peripheral capillary loops. It is in this subendothelial
localization that the immune complexes have access to circu-
lating inflammatory mediators such as complement and plate-
lets [14—171. Activation of inflammatory mediators, as well as
activation of monocyte macrophages and cytotoxic lympho-
cytes, not only stimulates proliferation of intrinsic glomerular
cells, but releases enzymes in the course of processing suben-
dothelial immune complexes that result in cellular necrosis. The
conditions under which subendothelial deposition occurs gen-
erally are associated with a vigorous antibody response with
antibodies of high affinity and avidity, which result in large
immune complexes of a molecular weight from one million to 10
million dalton. The large number and large size of these
complexes overloads the mesangial clearing system and pre-
vents sequestration of the immune complexes from the inflam-
matory mediators. Again, the nature of the antigen and the
antibody also might contribute to the predominance of suben-
dothelial localization [23—25]. Characteristics of certain anti-
bodies, such as cationic charge, could permit binding of com-
plexes that contain such antibodies to negative charges within
the glomerular capillary wall, thus accounting for their nephro-
tropism. If the complexes are large and highly cationic, they
will bind and fix to the closest anionic charges that are encoun-
tered; these happen to be in the subendothelial location. Fol-
lowing initial binding of what might be only a small population
of nephrotropic antibodies, activation of inflammatory cyto-
kines can increase the permeability of the capillary wall, thus
allowing other complexes to deposit. Other mechanisms may
well contribute to the glomerular subendothelial localization.
Some lupus antibodies are themselves cationic; others have
been identified that cross-react with native glomerular compo-
nents, including heparan sulfate proteoglycans and laminin.
Another significant factor is activation of endothelial adhesion
molecules. Induction of I-CAM and V-CAM expression is
associated with activation of cytokines, increased vascular
permeability, and initiation of the inflammatory response [34,
35]. Class-Ill and -IV lesions represent the most severe form of
glomerular involvement in patients with lupus because the
deposited immune complexes have access to inflammatory
mediators in the circulation and can initiate infiltration of
inflammatory cells and release of necrotizing enzymes [13, 17].
Patients with class-Ill or -IV pathologic lesions usually have
evidence of significant clinical renal disease, including protein-
uria frequently in the nephrotic range, renal insufficiency, and
an active urinary sediment [7, 11, 29, 30]. In some cases, these
lesions constitute the initial presentation of lupus erythemato-
sus and, in rare instances, these lesions are "silent" [6, 8]. The
immunopathogenesis underlying the renal disease in patients
with class-Ill or -IV lesions results in an unfavorable prognosis,
with a high percentage of patients eventually progressing to
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renal failure despite aggressive treatment. A major conse-
quence of severe glomerular inflammation with necrosis is the
development of glomerular scarring and sclerosis. With scarring
and necrosis resulting in a decrease of glomerular filtration
surface, a secondary process involving hyperperfusion and
hyperfiltration in remaining nephrons contributes to progressive
renal scarring and loss of function independent of the initial
inflammatory process.
The class-V lesion is a diffuse membranous glomerulonephrop-
athy. Light microscopy reveals a generalized diffuse thickening
of the peripheral capillary walls which, on silver methenamine
stains, exhibit a so-called "spike and dome" pattern. The
"spikes" are outward projections of membrane-like material
between "domes" that correspond to the subepithelial and
intramembranous deposits seen on immunofluorescence and
electron microscopy. Immunofluorescence demonstrates a clas-
sic confluent peripheral granular deposition of immunoglobu-
lins, which is occasionally accompanied by mesangial granular
deposits. Electron microscopy reveals a typical epimembra-
nous nephropathy with subepithelial and intramembranous de-
posits of varying electron density. The pattern is essentially
identical to that in idiopathic membranous glomerulonephrop-
athy, except for the presence of mesangial deposits. The
pathogenetic mechanism leading to this pattern of injury in
experimental animals is in-situ formation of immune complexes
[17]. This immune response is characterized by the presence of
small and unstable circulating immune complexes formed by
low-avidity or -affinity antibodies in the presence of antigen
excess. Under these conditions, the complexes can dissociate
and the antigen lodge in the glomerular capillaries. Subse-
quently, complexes are formed in situ, with immunoglobulins
attaching to their target antigen after the antigen has been
"planted" in the outer aspect of the glomerular basement
membrane. The nature of the antigen thus is a major determi-
nant in the pathogenesis of this lesion. The sera of all patients
with lupus contain antibodies directed against a number of
substances, including native and single-stranded DNA, his-
tones, and small ribonuclear proteins of both nuclear and
cytoplasmic origin. Of particular importance is that histones are
highly cationic, as I pointed out earlier. Good experimental and
clinical evidence indicates that cationic antigens have a high
affinity for the anionic sites of the glomerular basement mem-
brane [23]. Once bound to the glomerular basement membrane,
they can act as a target antigen and a focus for in-situ complex
formation. Since epimembranous deposits are also sequestered
from access to circulating inflammatory cytokines, the result is
simply a change in the glomerular permeability characteristics,
without evidence of necrosis or an active inflammatory re-
sponse. Thus, such patients would be predicted to have heavy
proteinuria as the prominent clinical feature and an indolent
course similar to that in patients with idiopathic membranous
nephropathy.
Although the initial biopsy findings in virtually all lupus
patients with renal involvement can be placed in one of these
five histologic classes, transformation from one class of renal
lesion to another can occur both spontaneously and following
treatment [29, 30]. The exact incidence of spontaneous trans-
formation is difficult to determine because relatively few serial
biopsy studies have been carried out in untreated patients.
Transformation of diffuse proliferative glomerulonephritis to a
predominantly membranous glomerulonephropathy or to a me-
sangial pattern has been observed in patients undergoing remis-
sion following aggressive therapy. The mechanism of transfor-
mation undoubtedly is related to an alteration of immune
responses in these patients and thus to an alteration of the
pathogenetic mechanisms involved in the generation of the
glomerular lesion. Serial biopsies therefore can give direct
information concerning modulation of the underlying disease
process.
Some additional pathologic features of importance to the
clinical assessment of these patients include glomerular capil-
lary thrombosis, vascular lesions, and tubular and interstitial
lesions. The presence of these complicating lesions may be
significant in individual cases given that the complicating lesion
might be the predominant one leading to clinical symptoms. Of
particular importance is the occurrence of glomerular capillary
thrombosis signifying intravascular coagulation [36]. Studies
have detected low levels of tissue-type plasminogen activator
and elevated levels of plasmin inhibitor in patients with glomer-
ular thrombosis associated with any pattern of lupus nephrop-
athy [37]. In addition, many patients have a lupus anticoagulant
now known to be an anti-phospholipid antibody [38]. Patients
with this lupus anticoagulant in their serum thus are subject to
glomerular thrombosis, which might be independent of the
presence of glomerular inflammation. In such patients, the
glomerular thrombosis is sometimes the primary pathogenetic
event and likely causes the progression of renal disease without
the participation of the accompanying immune responses.
Similarly, the presence of necrotizing vascular lesions also
appears to be a marker of poor prognosis in patients with lupus
nephritis [39]. The lesions can resemble the necrotizing arteri-
olitis seen with malignant hypertension and hemolytic-uremic
syndrome, or a true vasculitis characterized by fibrinoid necro-
sis of small arteries and arterioles surrounded by an inflamma-
tory infiltrate of the vessel wall. These lesions, reported in as
many as 10% of patients with lupus nephritis, generally are
considered an additional morbid factor. The presence of hyaline
arteriosclerosis is a morphologic indicator of the presence of
hypertension, a major comorbid factor [40] not only for renal
failure but also for patient survival [41].
Tubulo-interstitial disease is also important in the evaluation
of biopsies in SLE [42]. Active tubulo-interstitial nephritis is
commonly seen in patients with class-Ill or class-IV glomerular
lesions. The interstitial inflammation in these instances is com-
posed of lymphocytes and plasma cells, and, in some instances,
granulocytes and eosinophils. Interstitial fibrosis and the accu-
mulation of monocytes, macrophages, and plasma cells are
associated with more chronic disease. Immunofluorescence
studies occasionally reveal granular pentubular deposits in
active disease and, very rarely, the presence of linear deposi-
tion of immunoglobulins; the latter finding suggests an anti-
tubular basement membrane component. Of interest is the
observation that tubulo-interstitial disease progresses indepen-
dently of the glomerular lesion in some patients.
Clinical pathologic correlations from a number of studies,
including our own experience, have demonstrated a significant
relationship between the underlying renal histopathology and
the subsequent clinical course [41, 43—56]. Several of these
studies have emphasized the importance of using semiquantita-
tive analysis of the biopsy to assess severity of activity and
Nephrology Forum: Lupus nephritis: Lessons from the path lab 933
chronicity. Activity has been related to the presence of necro-
sis, cellular proliferation, leukocytic infiltration, and hyaline
thrombi in glomeruli, as well as tubular interstitial inflamma-
tion. Chronicity has been graded according to the degree of
glomeruloscierosis and fibrosis, as well as by the amount of
interstitial and tubular atrophy. Both the activity and chronicity
indexes have significant predictive value [29, 43, 45, 511.
The widely variable outcome of patients with lupus nephritis
has prompted clinicians to seek clinical and pathologic param-
eters by which to identify patients who are likely to have a poor
outcome and thus who warrant the most aggressive clinical
approach. A recent study evaluated the predictions of experi-
enced clinicians using clinical criteria they thought relevant and
compared these data with predictions based on a statistically
derived, computer-generated set of criteria. Predictions were
made both with and without the inclusion of biopsy informa-
tion. The criteria thought by the clinicians to be most useful in
predicting short-term outcome were serum creatinine at the
time of biopsy, 24-hour urinary protein, blood pressure, and
serum complement; those thought to be most useful for long-
term prognosis were serum creatinine, 24-hour urine protein
excretion, blood pressure, and hematuria [441. The computer-
generated clinical model identified serum creatinine, age, and
platelet count as the most important predictors of short-term
outcome, and length of disease, 24-hour urine protein excre-
tion, and serum complement for long-term outcome. Although
the predictions made by these clinicians were not improved
statistically when biopsy data were added to the clinical infor-
mation used, the level of confidence they expressed in their
predictions was higher when biopsy data were included. This
study concluded that experienced clinicians can indeed predict
the response of patients with lupus nephritis using clinical and
biopsy variables, but it also identified important clinical and
renal biopsy parameters that could have enhanced their predic-
tions but often were not utilized, as well as criteria that
contributed little but were believed by the physicians to be
important.
Esdaile has used elegant statistical analyses of the clinical
and pathologic data from patients in our own series [41, 43—47].
He evaluated the short-term prognosis of lupus nephritis by
assessing serum creatinine 12 months after renal biopsy [43].
The significant clinical and laboratory predictors included the
clinical signs of renal injury (serum creatinine, quantitative
urine protein excretion), older age, and coexisting hypertension
at the time of biopsy; the platelet count was found to be an
important independent laboratory parameter. Important biopsy
criteria included the presence of a diffuse proliferative nephritis
with a high activity score and subendothelial deposits. Indeed,
the strongest predictor of the short-term outcome was the
biopsy finding of subendothelial deposits. This conclusion con-
firms what we would have predicted from a knowledge of the
pathogenesis of subendothelial immune-complex deposition.
These findings demonstrate a definite incremental benefit of the
renal biopsy in identifying the patients in whom immunosup-
pressive agents might improve short-term outcome and con-
firmed the incremental benefit of evaluating the presence of
subendothelial deposits on biopsy, as noted by Whiting-
O'Keefe and colleagues [48] and the importance of determining
the activity index as reported by Magil and coworkers [55]. The
prognostic markers that predict a poor long-term outcome (for
example, renal insufficiency, renal failure, or death due to lupus
renal disease) include duration of disease before biopsy, overall
severity of disease, and the presence of vasculitis, hyperten-
sion, or a co-morbid ailment [42]. The best overall predictor
appears to be the extent of tubulo-interstitial disease on biopsy.
Cameron came to a similar conclusion for glomerular diseases
in general [42]. Given the chronicity and fluctuating nature of
the pathogenetic processes in lupus, it is not surprising that
prognostic factors can vary in their predictive power during the
course of the disease. Using a technique called spline analysis,
Esdaile has shown that renal outcomes are predicted signifi-
cantly by the activity index, the tubulo-interstitial index, and
the amount of subendothelial deposits on renal biopsy through-
out the course of the disease, whereas the laboratory findings
that clinicians generally prefer as important predictors were
useful prognostic markers only in the early years post biopsy
[46]. Measures of overall disease activity such as SLEDAI and
Le Riche indices proved useful only in later years.
We observed that patients with similar degrees of disease
activity and biopsy findings who experienced a longer interval
between disease onset and biopsy had poorer long-term out-
comes. This finding prompted us to examine whether delayed
treatment with immunosuppressive agents adversely affected
outcome [47]. The rate of deterioration in serum creatinine and
24-hour urinary protein over time from disease onset to renal
biopsy correlated with the activity and chronicity indices as
well as with the abundance of subendothelial deposits, all of
which are criteria for poor prognosis. This analysis suggests
that early treatment of patients with a class-IV lesion with
abundant subendothelial deposits on a biopsy is of benefit, and
prompt use of immunosuppressive drugs is indicated. To the
extent that findings from renal biopsy provide a rationale for the
use of potentially toxic drugs, the procedure is worthwhile.
This brings us to yet another question. What is the value of
repeat biopsy in patients with lupus nephritis, and when is it
indicated? In our series, nearly one-half the patients had a
second biopsy at a median of 25 months after the first [45]. A
comparison of the two biopsies revealed that the prevalence of
proliferative lupus nephritis of WHO classes III and IV de-
creased with time and that mesangial class II and membranous
class V increased. Activity index and subendothelial deposits
declined; the chronicity index and subepithelial deposits in-
creased. While these changes may reflect a response to therapy,
we also observed that the relative change in the amount of
mesangial or subendothelial deposits best identified the patients
at risk for developing renal impairment and renal insufficiency,
and consequently dying. The results confirm the importance of
immune-complex deposition as measured by electron micros-
copy in the pathogenesis of lupus nephritis, and suggest that the
control of this process by immunosuppressive therapy indeed
alters renal function and prognosis. Our study further suggests
that monitoring the response to therapy is valuable in managing
these patients [45], as illustrated by the patient presented today.
Although I am a pathologist, I cannot conclude without a final
word about therapy. Studies of large groups of patients from a
variety of centers all have confirmed the value of aggressive
steroid and cytotoxic therapy in the modulation of the renal
injury associated with lupus erythematosus. While the overall
morbidity and mortality of lupus nepbritis have improved with
the advent of such therapy, some patients have received
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long-term therapy and have not fared well. Attempts at increas-
ing the effectiveness of therapy have focused on new immuno-
suppressive agents as well as on the use of plasmapheresis and
extracorporeal photochemotherapy. A controlled trial of plas-
mapheresis plus a standard regimen of prednisone and cyclo-
phosphamide did not demonstrate an improvement in clinical
outcome [57]. Anecdotal reports, however, prompted a ran-
domized trial of cyclic plasmapheresis and subsequent pulse
cyclosphosphamide in severe lupus, the results of which are not
yet available [581. This study is based on the rationale that
synchronization of plasmapheresis and subsequent pulse cyto-
toxic therapy might enhance the deletion of pathogenetic
clones. Since extracorporeal photochemotherapy was sug-
gested as being useful for T-lymphocyte-mediated diseases,
anecdotal reports have suggested that this method might pro-
duce clinical improvement of lupus [59].
Further advances are needed in the treatment of severe lupus
erythematosus, both to reduce the current mortality rate of 10%
to 20% after 10 years and to decrease the development of renal
insufficiency requiring dialysis, which occurs in nearly one-
quarter of patients. Also, efforts must continue to minimize the
adverse effects of long-term immunosuppression.
Questions and answers
Da. ASGHAR RASTEGAR (Associate Director of Education,
Dept. of Internal Medicine, Yale University, New Haven,
Connecticut): You stressed the value of renal biopsy in the
management of patients with systemic lupus. As you know, on
occasion patients present without any clinical or laboratory
evidence of renal involvement, but with significant abnormali-
ties on renal biopsy. My question is: when should a patient with
active lupus but no overt evidence of renal disease be biopsied?
DR. KASHGARJAN: Any young child who has lupus, even
without evidence of renal disease, should be biopsied if the
clinical manifestations of lupus are severe, that is, marked
systemic symptoms, not just an occasional arthritis or a mild
skin lesion. The problem in adults is more difficult, and our
study suggests that an early biopsy is extremely important [47].
Waiting until you find significant proteinuria and an active
sediment has an adverse effect. I think the question comes
down to: how do we know which patients have silent lupus
nephritis and which patients don't? I don't have a good answer.
On the one hand, if they have proteinuria or any evidence of
renal disease, I think they should be biopsied. If they don't have
any such evidence, I think perhaps the indication would be the
severity of their extrarenal manifestations, just as in children; if
these are severe, that is, cerebritis or severe serositis, one
might predict that renal disease also is present. On the other
hand, I've seen individual cases where that argument did not
hold up.
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York at Stony Brook, Stony Brook, New
York): I would like to press you a little bit on the value of biopsy
in the management of patients. There is no question that the
renal biopsy has been absolutely essential in our understanding
of the morphologic variability underlying clinical syndromes
and in unraveling the pathogenetic mechanism at play. There is
also no question that proper stratification of patients in prospec-
tive clinical trials requires the information from a renal biopsy.
But the question is: in managing individual patients in the real
world, that is, in the absence of a well-designed study, how
important is the information gleaned from a biopsy in the actual
outcome? It's one thing to say that a delayed biopsy shows you
more evidence pathologically of the predictors of chronicity and
that the predictors of activity may be more evident in biopsies
obtained later rather than earlier in the clinical course of lupus.
It's quite another to say that the availability of that information
sooner would have resulted in a better outcome. How do we
know that the clinician's hand can't be guided just as well
towards good outcomes in the absence of a biopsy? I think more
and more we are going to be obligated to devise our manage-
ment strategies on the basis of patient outcomes, and not simply
on the basis of clinicopathologic correlations.
Da. KASHGARIAN: That's a good question. I think the biopsy
does two things. (1) It separates patients who have the most
severe lesions from patients who don't require any therapy. For
example, it separates class IV from class II and class V. All
patients in these classes would have proteinuria clinically, and
only a biopsy would let you would know which ones to treat
aggressively with cytotoxic and potentially dangerous therapy.
You could treat them all, but it probably is more prudent not to
treat patients who have mesangial lesions or membranous
lesions because cytotoxic drugs have not been proven to be of
any value in those lesions. (2) Renal biopsy identifies patients
who require more aggressive therapy, therapies that are con-
sidered experimental, if you will, or more dangerous. As a
pathologist, I always like to talk about therapy because I don't
have to worry about it! But clinicians often consider treating
patients with plasmapheresis, photopheresis, or another new
approach. The study from Lewis and colleagues suggests that
plasmapheresis plus cytotoxic therapy is of no value and
actually might be harmful [57]. On the other hand, a German
group has said that the Lewis study did not use plasmapheresis
correctly [58]. We want to target the lymphocytes that are
becoming plasma cells; therefore we ought to use plasmaphere-
sis without immunosuppression to elicit the rebound phenom-
enon and to increase the level of immune response. The bad
lymphocytes that are producing the bad antibodies will be
stimulated so we can zap them with immunosuppression. You
wouldn't want to use that kind of therapy in all patients, only in
patients who have a very high activity index. Biopsy would
separate out patients with poor long-term prognosis from those
who are going to be relatively well.
Much of what I have said relies on the ability of the
pathologist to assess the acute and chronic severity of the
biopsy lesion. Schwartz and coworkers have challenged the
value of activity and chronicity indices [60, 61]. They found
poor correlation among the scores of four different pathologists.
That is not surprising, since reproducibility among pathologists
is notably variable in the diagnosis of many different lesions,
and glomerular disease is no exception. On the other hand, I
believe that the experienced renal pathologist can consistently
assess severity with or without a semiquantitative index tech-
nique. Even Dr. Schwartz, when he was trying not to be
consistent, had a reasonably high correlation with himself in
setting indices. Furthermore, although they don't like the
semiquantitative indices, this same group in 1987 stressed "the
significance of accurate assessment of renal biopsy material in
patients with lupus nephritis in order to determine their prog-
nosis" (their own words). I also agree with them that the
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amount of acute inflammatory change in glomeruli and consid-
eration of chronicity of the interstitium are important prognos-
tic indicators [621. Isn't that what activity and chronicity indices
are?
DR. ALAN KLIGER (Nephrology Section, Yale University
School of Medicine): I might be asking the same question in a
slightly different way. You've analyzed your data looking at
predictors of outcome. But the clinician and patient are inter-
ested over the shorter term in the predictors of the response to
therapy. Have you analyzed your data that way?
DR. KASHGARIAN: We have not analyzed it that way. The
one-year outcome data are more or less such an examination,
but we haven't addressed that specific question. I was trying to
answer that question before, namely, what value does the
biopsy have in separating out patients in whom you want to
change the immune response, and can we predict that these
patients will respond to therapy?
DR. REINALDO MARTINELLI (Renal Service, Federal Univer-
sity of Bahia, Bahia, Brazil): Could you comment about the use
of intravenous cyclophosphamide on the appearance of the
renal biopsy, specifically fibrin disposition?
DR. KASHGARIAN: We don't know what the specific effects of
any therapeutic modality are on modifying the histologic ap-
pearance of the immune response. The question of intravenous
versus oral cytotoxic therapy has more to do with morbidity of
the therapeutic manipulation than with any specific manipula-
tion of the immune response.
DR. MARGARET BIA (Nephrology Section, Yale University):
We've known for a long time that the finding of glomerular
thrombi on biopsy is a poor prognostic sign. Are patients with
this pathologic finding the same ones who have detectable
anti-cardiolipin in their serum? Also, do patients with lupus
who are positive for anti-cardiolipin have a higher frequency of
renal disease?
DR. KASHGARIAN: Only some patients who have glomerular
thrombi have detectable levels of anti-cardiolipin. Of all pa-
tients with lupus, about 30% to 40% have anti-cardiolipin, but
not all of these have capillary or large vessel thrombosis. In
other words, patients can have thrombosis without anti-cardi-
olipin and anti-cardiolipin without thrombosis. Patients who
have anti-cardiolipin and thrombosis have a poor prognosis, but
we don't know which individual patients will develop thrombo-
sis.
DR. FREDERICK FINKELSTEIN (Clinical Professor of Medi-
cine, Yale University): I'd like to return to the question of the
usefulness of the biopsy in therapeutic decisions. It's fairly easy
when the biopsy confirms your clinical impression of severe
lupus nephritis, but perhaps you could comment on the circum-
stances in which there's a discrepancy between what one
expects from the clinical presentation and what one actually
finds in the biopsy specimen. Consider, for example, a patient
with low-grade proteinuria, normal renal function, and normal
serum complement levels who on biopsy has extensive suben-
dothelial deposits without necrosis. What are the therapeutic
implications of such a biopsy for the clinician?
DR. KASHGARIAN: If I'm to utilize the paradigm that I
presented, I would say that the lesion tells me more than the
patient does. If subendothelial deposits are present, the patient
should be treated aggressively. Waiting to treat that patient
until the glomerular damage is so severe that it is clinically
manifest is doing damage to the kidney and not approaching
that patient rationally from an immunopathogenetic point of
view. It is important when there is this discrepancy to place
greater weight on the biopsy findings than on the clinical
findings. I believe our studies support this point of view. The
predictors were heavily weighted toward the biopsy and the
presence of subendothelial deposits.
DR. COHEN: I'm still having trouble with that logic. Finding
that the biopsy looks worse ii you delay obtaining it for some
months after the clinical onset is different than finding that
treating at those two different times produces a different out-
come. Do we really know that treating patients with lupus who
have little if any clinical manifestations of renal disease leads to
better outcomes than waiting until clinical manifestations are
present?
DR. KASHGARIAN: No, we don't know that. But pathologists
have intuitions just as clinicians do. And I am basing my
intuition on knowledge about the pathogenesis. If I see lots of
subendothelial deposits, I accept that as evidence of a condition
associated with a vigorous antibody response, in which the
antigen is going to be nephrotopic, is going to localize to the
glomerulus, and therefore is going to initiate an inflammatory
response. I would want to modify that patient's immunologic
response. That's why I say that the biopsy tells me more than
the patient does.
DR. COHEN: Rational, but not based on patient outcome data.
DR. KASHGARIAN: Right.
DR. KERRY COOPER (Nephrology Section, Yale University
School of Medicine): Would you comment further on the
platelet count as a prognostic guide in patients with lupus? Do
you think this association tells us anything about the pathoge-
netic process? And finally, how well documented is the view
that anti-platelet therapy is not beneficial in patients with lupus
nephritis?
DR. KASHGARIAN: We haven't looked at that important
question. A low platelet count is probably associated with a
greater degree of endothelial activation, platelet consumption,
and activation of the inflammatory response, with platelets
being an important mediator of that inflammatory response. If
that is so, then yes, indeed, anti-platelet therapy should be
considered. Anti-platelet therapy, however, is basically just
another form of anti-inflammatory treatment but one that en-
gages the effector arm of the inflammatory response way down
the line. Preventing platelet activation and the release of
platelet cytokines (for example, PDGF) could modulate events
that are distal to the initiating immune reaction. Anti-platelet
therapy therefore might be valuable in attenuating, but is not
likely to abort, the inflammatory response. It may yet prove to
have a role in combination with other therapy aimed at modu-
lating the immune response.
DR. PETER ARONSON (Professor of Medicine [Nephrology]
and Cellular and Molecular Physics, Yale University): I have a
question about the difference between lupus nephritis patients
with and without hypertension. Is the poorer prognosis in
patients with hypertension a reflection of worse pathologic
findings? Has the effect of treatment with ACE inhibitors or
calcium-channel blockers been studied in these patients?
DR. KASHGARIAN: Hypertension and arteriolar nephroscle-
rosis are most likely the sequelae of severe disease and not
directly related to the immunologic aspects of lupus. If the renal
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disease is severe, the patient is likely to develop hypertension;
hypertension causes arteriolar sclerosis, which leads to fixed
hypertension; and fixed hypertension causes more severe or
more rapid progression of renal insufficiency, which by this
time is mediated by both the primary glomenilar disease and the
secondary vascular sequelae. My sense is that they are inde-
pendent, co-morbid factors and that hypertension is a very
important co-morbid factor. Nephrologists seem to pay more
attention to hypertension than do rheumatologists, and I think
the control of blood pressure is a very important part of the
management of those patients.
DR. PETER HERBERT (Clinical Professor of Medicine, Yale
University): You correlated some of the pathologic findings you
described to the sizes of the immune complexes involved. Can
you look at that relationship from the other direction and
predict the renal pathology from an evaluation of the sizes of
the immune complexes in circulation?
DR. KASHGARIAN: Although not demonstrated very well in
humans, in animals the relationship is really very clear. The
initial data that I presented are derived from animal experimen-
tation. Attempts have been made to study the problem in
humans but, to do so convincingly, one would need to have
large amounts of serum and very good extraction and sizing
techniques. Such studies have not been done in large numbers
of patients. I think that Eng Tan has a serum bank and is doing
some studies along those lines right now, but I don't think the
data have been published.
Da. COHEN: I have a related question. You pointed out how
the size and cationic nature of the antigen/antibody complex in
the circulation are important in determining the pathologic
picture. Can one use this information to direct therapy? For
example, can one alter the charge on a circulating complex or
change its size or change its affinity for glomerular structures?
DR. KASHGARIAN: That is a new area of interest. Clinicians
are looking for new methods of treating lupus. Any kind of
immune modulation that affects the kind of antibody reponse is
a rational approach to therapy. Some evidence also indicates
that protein processing, for instance, ubiquitinization or the
initiation of stress responses, may be important therapeutic
targets. Translation of these ideas into a therapeutic modality
has not yet been accomplished.
DR. DAVID ELLISON (Nephrology Section, Yale University
School of Medicine): You noted that lupus patients with mem-
branous nephropathy—the type-V lesion—had a reasonably
good prognosis and required less aggressive therapy. Nephrol-
ogists seem more and more inclined to treat idiopathic mem-
branous nephropathy with cytotoxic agents. Do you advocate
the use of cytotoxic agents in lupus patients with membranous
lesions?
DR. KASHGARIAN: I think type-V lesions are less problematic
for patients than type-IV lesions are. Whether they are better or
worse than idiopathic membranous nephropathy, I don't know.
Our experience has been that membranous lupus very rarely is
seen as the initial presentation. It is much less frequent than
what has been reported in the literature. I don't know the
natural history of membranous nephropathy in lupus. I suspect
that it is no different from that of idiopathic membranous
nephropathy. Patients with idiopathic membranous nephropa-
thy do vary in their natural history: some have a very aggressive
and rapid course; others have a more indolent course. I don't
know how to explain the difference.
DR. COHEN: You emphasized the importance of mesangial
clearing of the circulating complexes and endorsed the hypoth-
esis that overflow from the mesangium might be an important
factor in the glomerular inflammation that characterizes class-I!
and class-Ill disease. Are there any vascular beds in the body,
other than the glomerular mesangium, that function to clear
circulating immune complexes? If so, could such vascular beds,
or the glomerular mesangium itself, be stimulated therapeuti-
cally to do a better job of clearing?
DR. KASHGARIAN: The glomerular mesangium is unique both
in its anatomic configuration and in the amount of blood flow it
receives. But it is not unique in terms of processing circulating
immune complexes. The entire reticuloendothelial system, in-
cluding the liver and spleen, is involved in the processing of
circulating immune complexes. The glomerulus is unique be-
cause it receives 25% of the blood flow. It gets as much blood
flow as the brain and so is subject to a higher permanent dosage
of immune complexes. The glomerular mesangium is also
unique in having a mechanism for sieving and processing
macromolecules that are not filtered through the glomerulus.
The general reticuloendothelial system has limited capacity but
probably plays a role when a very vigorous response with large
amounts of immune complexes is present.
DR. COHEN: Is it possible to stimulate the reticuloendothelial
system to do better?
DR. KASHOARIAN: There are ways of stimulating the reticu-
loendothelial system but, again, it has a limited capacity.
DR. COHEN: Being an autoimmune disease, lupus presumably
has a strong genetic basis. What is known about the genetic
determinants of lupus, in general, and about the individual
forms of lupus renal disease in particular? Has the genetic basis
for the marked female preponderance of this disease been
established?
DR. KASHGARIAN: We are getting increasing information
concerning the genetic basis of lupus. HLA-DR2 and DQw1 are
associated with younger onset and heightened response,
whereas DQw2 is associated with older onset and Ro and La
antibodies. T-cell receptor genes are also potential contributors
to the types of lesions that we encounter. However, other
important factors, like environmental factors, exposure to
antigens, and exposure to viruses, might stimulate B-cell re-
sponses nonspecifically. Patients who are more susceptible to
polyclonal B-cell activation might selectively direct that activa-
tion toward autoantigens. That evidence is beginning to come
in. The female preponderance might be related to other modu-
lating factors, namely, those related to hormonal control of
immune responses, as in pregnancy. Experimental studies
certainly suggest an important role for hormones. In the mouse
model of lupus, males have a much lower incidence of signifi-
cant lesions than females do, but castrated males given estrogen
have an equivalent incidence. So genetic, environmental, and
humoral factors must be considered.
DR. JOHN HAYSLETT (Nephrology Section, Yale University,
School of Medicine): Dr. Geisser, you are currently following
the patient presented. How she is doing?
DR. DANIEL GEISSER (Assistant Clinical Professor of Medi-
cine, Yale University): After we received the results of the renal
biopsy, which showed subendothelial deposits and necrosis, we
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reinstituted 60 mg prednisone and 50 mg cyclophosphamide.
Her serum creatinine concentration was 2.0 mg/dl at that time.
It is now 6 months since we started, and I am pleased to report
that her serum creatinine is now 1.1 mg/dl and her urine protein
excretion is down to 1.8 g/day. She continues to take cyclo-
phosphamide, 50 mg/day, and prednisone, 5 mg every other
day.
DR. KASHGARIAN: Wonderful news! I hope I have been able
to convince the skeptics that we can learn something from the
biopsy that is useful to the patient.
Reprint requests to Dr. M. Kashgarian, Director, Diagnostic Elec-
tron Microscopy and Renal Pathology, Yale University School of
Medicine, 20 Lauder Hall, P.O. Box 3333, New Haven, Connecticut
06510-8023, USA
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